Papel del PAI-1 en los procesos trombóticos

Medicina Clinica

Volumn 113, Issue 2, 1999, Pages 63-69

  Orbe, Josune ^a   Montes, Ramón ^a   Paramo J A ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; VITRONECTIN;

CHEMISTRY; GENETIC POLYMORPHISM; GENETICS; HUMAN; METABOLISM; REVIEW; THROMBOSIS;

FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; THROMBOSIS; VITRONECTIN;

EID: 0039251134     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (115)

1. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombosis. Blood 1991; 78: 3.114-3.124.
2. Vassalli JD, Sappino JD, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1.067-1.072.
3. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387.
4. Fay WP, Shapiro AD, Shih JL, Schleef RD, Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327: 1.719-1.733.
5. Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436.
6. Verheijen JH, Chang GIC, Kluft C. Evidence for the occurrence of a fast acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984; 51: 392-395.
7. Kruithof EK, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913.
8. Van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (anti-activator) synthesized by endothelial cells. J Biol Chem 1984; 259: 14.914-14.921.
9. Arndt A, Murphy P, Hart AJ. Human HuH-7 hepatoma cells express urokinase and plasminogen activator inhibitor-1: indentification, characterization and regulation by inflammatory mediators. Biochim Biophys Acta 1992; 1.138: 149-156.
10. Chapman HA, Yang X, Sailor LZ, Sugarbaker DJ. Developmental expression of plasminogen activator inhibitor type 1 by human alveolar macrophages. J Immunol 1990; 145: 3.398-3.405.
11. Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, Van Zonneveld AJ et al. Endothelial plasminogen activator inhibitor (PAI): a new member of the serpin gene family. EMBO J 1986; 5: 2.539-2.544.
12. Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78: 1.670-1.673.
13. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature (Lond) 1992; 355: 270-273.
14. Van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1 and its function in fibrinolysis: an update. Fibrinolysis 1995; 9: 263-276.
15. Lindahl TL, Sigurdardottir O, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 1989; 62: 748-751.
16. Sancho E, Declerck PJ, Price NC, Kelly SM, Booth NA. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate and cleaved forms. Biochemistry 1995; 34: 1.064-1.069.
17. Preissner KT. Structure and biological role of vitronectin [revisión]. Annu Rev Cell Biol 1991; 7: 275-310.
18. Ehrlich HJ, Klein Gebbink R, Preissner KT, Keijer J, Esmon NL, Mertens K et al. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell in matrix. J Cell Biol 1991; 115: 1.773-1.781.
19. Ehrlich HJ, Klein Gebbink R, Keijer J, Pannekoek H. Elucidation of structural requirements on plasminogen activaor inhibitor 1 for binding to heparin. J Biol Chem 1992; 267: 11.606-11.611.
20. Keijer J, Linders M, Van Zonneveld AJ, Ehrlich HJ, De Boer JP, Pannekoek H. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physioligic relevance. Blood 1991; 78: 401-409.
21. Lawrence D, Loskutoff DJ. Inactivation of plasminogen activator inhibitory by oxidants. Biochemistry 1986; 25: 6.351-6.355.
22. Sakata Y, Loskutoff DJ, Gladstone CL, Hekman CM, Griffin JH. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 1986; 68: 1.218-1.223.
23. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human β-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6.776-6.780.
24. Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arvelier D et al. Five frequent polymorphisms of the PIA-1 gene. Arterioscler Thromb Vasc Biol 1997; 17: 851-858.
25. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1995; 96: 1.621-1.630.
26. Van den Berg EA, Sprengers ED, Jaye M, Burgess W, Maciag T, Van Hinsbergh VWM. Regulation of plasminogen activator inhibitor-1 mRNA in human endothelial cells. Thromb Haemost 1988; 60: 63-57.
27. Van Hinsberg VWM, Kooistra T, Van den Berg EA, Princen HMG, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988; 72: 1.467-1.473.
28. Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. J Biol Chem 1989; 264: 10.396-10.401.
29. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. J Biol Chem 1991; 266: 2.459-2.465.
30. Schneider DJ, Nordt TK, Sobel BE. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes 1992; 41: 890-895.
31. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991; 181: 902-906.
32. Fujii S, Lucore CL, Hopkins WE, Billadello JJ, Sobel BE. Induction of synthesis of plasminogen activator inhibitor type-1 by tissue-type plasminogen activator in human hepatic and endothelial cells. Thromb Haemost 1990; 64: 412-419.
33. Konkle BA, Kollros PR, Kelly MD. Heparin-binding growth factor-1 modulation of plasminogen activator inhibitor-1 expression. J Biol Chem 1990; 265: 21.867-21.873.
34. Fujii S, Sawa H, Sobel BE. Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by Gemfibrozil. Thromb Haemost 1993; 70: 642-647.
35. Orbe J, Montes R, Zabalegui N, Hermida J, Páramo JA, Rocha E. Effect of heparin and hirudin on PAI-1 expression by human umbilical vein endothelial cells [resumen]. Haemostasis 1996; 26 (Supl 3): 261.
36. Chordá C, Páramo JA, Rocha E. Comparison of the effect of unfractionated heparin, low molecular weight heparin and hirudin (RevascTM) on the fibrinolytic potential of cultured human umbilical vein endothelial cells. Fibrinolysis 1996; 10: 43-48.
37. Konkle BA, Schuster SJ, Kelly MD, Harjes K, Hasset DE, Bohrer M et al. Plasminogen activator inhibitor-1 messenger RNA expression is induced in rat hepatocytes in vivo by dexamethasone. Blood 1992; 79: 2.636-2.642.
38. Fattal PG, Schneider DJ, Sobel BE, Billadello JJ. Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J Biol Chem 1992; 267: 12.412-12.415.
39. Loskutoff DJ, Sawdey M, Keeton M, Schneiderman J. Regulation of PAI-1 gene expression in vivo. Thromb Haemost 1993; 70: 135-137.
40. Quax PHA, Van den Hoogen M, Verheijen JA, Padro T, Zeheb R, Gelerther TD et al. Endotoxin induction of plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem 1990; 265: 15.560-15.563.
41. Keeton M, Eguchi Y, Sawdey M, Ahn C, Loskutoff DJ. Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein murine renal tissue. Am J Pathol 1993; 142: 59-70.
42. Wang Y, Thompson EM, Whawell SA, Fleming K. Expression and localization of plasminogen activator inhibitor 1 mRNA in transplant kidneys. J Pathol 1993; 169: 445-450.
43. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6.998-7.002.
44. Chomiki N, Henry N, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994; 72: 44-53.
45. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13: 1.090-1.100.
46. Amman V, Nilsson A, Stemme S, Risberg B, Rymo L. Expression of plasminogen activator inhibitor 1 mRNA in healthy atherosclerotic and thrombotic human arteries and veins. Thromb Res 1994; 76: 487-499.
47. Grancha S, Estellés A, Falcó C, Chirivella M, España F, Aznar J. Detailed localization of type-1 plasminogen activator inhibitor mRNA expression and antigen in atherosclerotic plaque on human coronary artery. Fibrinol Proteol 1998; 12: 53-60.
48. Thorton AJ, Gelehrter TD. Human hepatocytes express the gene for type 1 plasminogen activator-inhibitor (PAI-1) in vivo. Fibrinolysis 1995; 9: 9-15.
49. Schneiderman J, Sawdey M, Craig H, Thinnes T, Bordin G, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene expression following partial hepatectomy. Am J Pathol 1993; 143: 753-762.
50. Booth NA, Simpson AJ, Croll A, Bennet B, McGregor IR. Plasminogen activator inhibitor (PAI-1 in plasma and platelets). Br J Haematol 1988; 70: 327-333.
51. Alessi MC, Chomiki N, Berthier R, Schweitzer A, Fossat C, Juhan-Vague I. Detection of plasminogen activator inhibitor-1 (PAI-1) mRNA in human megakaryocytes by in situ hybridization. Thromb Haemost 1994; 72: 931-936.
52. Colucci M, Páramo JA, Collen D. Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by fast-acting inhibitor of plasminogen activator in vitro and in vivo. J Lab Clin Med 1986; 108: 53-59.
53. Braaten JV, Jerome HWG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor-1: light scattering and ultraestructural examination of lysis of a model of platelet-fibrin thrombus. Blood 1993; 81: 1.290-1.299.
54. Páramo JA, Rocha E. Ritmo circadiano de los componentes fibrinolíticos sanguíneos. Rev Iberoam Thromb Hemost 1994; 7: 232-236.
55. Rocha E, Páramo JA. Fibrinólisis y trombosis. En: Castillo J, Martínez-Vila E, editores. Trombosis, fármacos antitrombóticos y enfermedad cerebrosvascular. Barcelona: Ediciones J. Uriach, 1995; 115-141.
56. Aznar J, Estellés A. Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery disease. Haemostasis 1994; 24: 243-251.
57. Rocha E, Páramo JA. The relationship between impaired fibrinolysis and coronary heart disease: a role for PAI-1. Fibrinolysis 1994; 8: 294-303.
58. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusion in mice transgenic for plasminogen activator inhibitor gene. Nature (Lond) 1990; 346: 74-76.
59. Carmeliet P, Stassen JM, Schoonjans L, Ream B, Van den Oord JJ, De Mol M et al. Plasminogen activator inhibitor-1-gene-deficiente mice. II. Effects on haemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2.756-2.760.
60. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Shen C, Newcomer LM et al. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992; 85: 1.822-1.827.
61. Nilsson JM, Ljunger H, Tenbgorn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentrations of plasminogen activator inhibitor. Br Med J 1985; 290: 1.453-1.456.
62. Osterman H, Koening S, Kienast J, Schmitz-Huebner U. Increased plasminogen activator inhibitor in patients with idiopathic deep venous thrombosis. Fibrinolysis 1988; 2: 88-89.
63. Páramo JA, De Boer AC, Colucci M, Jonker JJC, Collen D. Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep venous thrombosis. Thromb Haemost 1985; 54: 725.
64. Juhan-Vague I, Alessi MC, Fossat C, Valadier J, Aillaud MF, Serradimigni A. Clinical relevance of reduced t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987; 57: 67-72.
65. Falkon L, Borrel M, Sala N, Félez J, Martín S, Grau E et al. Fibrinolytic abnormalities. A spanish multicenter study on 443 patients with venous thromboembolic disease. Thromb Res 1992; 66: 455-460.
66. Tabernero MD, Estellés A, Vicente V, Alberca I, Aznar J. Incidence of increased plasminogen activator inhibitor in patients with deep venous thrombosis and/or pulmonary embolism. Thromb Res 1989; 56: 565-570.
67. Engesser L, Brommer EJP, Kluft C, Briet E. Elevated pasminogen activator inhibition (PAI), a cause of thrombophilia? A study in 203 patients with familiar of sporadic venous thrombophilia. Thromb Res 1989; 62: 673-680.
68. Bolan CD, Krishnamurti C, Tang DB, Carrington LR, Alving BM. Association of protein S deficiency with thrombosis in a kindred with increased levels of plasminogen activator inhibitor-1. Ann Intern Med 1993; 119: 779-785.
69. Jorgensen M, Bonnevie-Nielsen V. Increased concentration of the fast-acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis. Br J Haematol 1987; 65: 175-180.
70. Kluft C, Verheijen JH, Jie AF, Rijken DC, Preston FE, Sue-Ling HM et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast acting inhibitor of tissue type plasminogen activator after trauma. Scand J Clin Invest 1985; 45: 605-610.
71. D'Angelo A, Kluft C, Verheijen JH, Rijken DC, Mozzi E, Mannucci PM. Fibrinolytic shutdown after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor. Eur J Clin Invest 1985; 15: 308-312.
72. Páramo JA, Alfaro MJ, Rocha E. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor. Relationship to deep vein thombosis and influence of prophylaxis. Thromb Haemost 1985; 54: 713-716.
73. Sue-Ling HM, Davies JA, Prentice CRM, Verheijen JH, Kluft C. Effects of oral stanazolol used in the prevention of postoperative deep vein thrombosis on fibrinolytic activity. Thromb Haemost 1985; 53: 141-142.
74. Rocha E, Alfaro MJ, Páramo JA, Cañadell J. Preoperative identification of patients at high risk of deep vein thrombosis despite prophylaxis in total hip replacement Thromb Hemost 1988; 59: 93-95.
75. Eriksson BI, Eriksson E, Gyzander E, Teger-Nilsson AC, Risberg B. Thrombosis after total hip replacement. Relationship to the fibrinolytic system. Acta Orthop Scand 1989; 60: 159-163.
76. Pãramo JA, Rocha E. Nuevos conceptos sobre el papel de la hemostasia en la patogenia y tratamiento de la sepsis. Med Clin (Barc) 1994; 103: 260-263.
77. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1.165-1.172.
78. Páramo JA, Pérez JL, Serrano M, Rocha E. Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis. Thromb Haemost 1990; 64: 3-6.
79. Pralong G, Calandra T, Glauser MP, Schellekens J, Verhoef J, Bachmann F et al. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost 1989; 61: 459-462.
80. Llorente JA, Garcia-Frade LJ, Landin L, De Pablo R, Torrado C, Renes E et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993; 103: 1.536-1.542.
81. Vicente V, Estellés A, Moraleda JM, España F, Aznar J. Fibrinolytic changes during acute vascular damage induced by mediterranean spotted fever. Fibrinolysis 1993; 7: 324-329.
82. Gómez C, Páramo JA, Colucci M, Rocha E. Effect of heparin and/or antithrombin III on the generation of endotoxin-induced plasminogen activator inhibitor. Thromb Haemost 1989; 62: 694-698.
83. Paloma MJ, Páramo JA, Rocha E. Effect of DDAVP on endotoxin-induced intravascular coagulation in rabbits. Thromb Haemost 1992; 68: 306-309.
84. Paloma MJ, Páramo JA, Rocha E. Endotoxin-induced intravascular coagulation in rabbits: Effect of tissue plasminogen activator vs urokinase on PAI-1 generation, fibrin deposits and mortality. Thromb Haemost 1995; 74: 1.578-1.582.
85. Hermida J, Montes R, Péramo JA, Rocha E. Endotoxin-induced disseminated intravascular coagulation in rabbits: effect of recombinant hirudin on hemostatic parameters, fibrin deposits and mortality. J Lab Clin Med 1998; 131: 77-83.
86. Páramo JA, Colucci M, Collen D, Van der Werf F. Plasminogen activator inhibitor in the blood of patients with coronary disease. Br Med J 1985; 291: 573-574.
87. Aznar J, Estellés A, Tormo G, Sapena P, Tormo V, Blanch S et al. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59; 535-541.
88. Oloffson BO, Dahlén G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10: 77-82.
89. Hamsten A, Ericksson P. Fibrinolysis and atherosclerosis: an update. Fibrinolysis 1994; 8 (Supl 1): 253-262.
90. ECAT Angina Pectoris Study Group. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3,000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17.
91. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG, on behalf of the ECAT Study Group. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2.057-2.063.
92. Hamsten A, Wiman B, De Faire U, Blomback M. Increased plasma levels of rapid inhibitor of tissue plasminogen activator in joung survivors of myocardial infarction. N Engl J Med 1985; 313: 1.557-1.563.
93. Gray R, Yudkin JS, Patterson DLH. Plasminogen activator inhibitor-a risk factor for myocardial infarction in diabetic subjects. Br Heart J 1993; 69: 228-232.
94. Chandler WL, Stratton JR. Laboratory evaluation of fibrinolysis in patients with a history of myocardial infarction. Am J Clin Pathol 1994; 102: 248-252.
95. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
96. Hamster A. The hemostatic system and coronary heart disease. Thromb Res 1993; 70: 1-38.
97. Andreotti F, Davies GJ, Hackett DR, Khan MI, De Bart AC, Aber VR et al. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988; 62: 635-637.
98. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993; 70: 138-143.
99. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF. Relationship between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diabetes Metabol 1987; 13: 331-336.
100. Portter van Loon BJ, Kluft C, Radder JK, Blankestein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993; 42: 945-949.
101. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-660.
102. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibitor capacity, plasma insulin and triglyceride levels in nondiabetic obese subjects. Thromb Haemost 1987; 57: 326-328.
103. Estellés A, Aznar J, Tormo G, Sapena P, Tormo V, España F. Influence of a rehabilitation sports programme on the fibrinolytic activity of patients after myocardial infarction. Thromb Res 1989; 55: 203-212.
104. Páramo JA, Olavide I, Barba J, Montes R, Panizo C, Muñoz MC et al. Long-term cardiac rehabilitation program favorably influence fibrinolysis and lipid concentrations in acute myocardial infarction. Haematologica 1998; 83: 519-524.
105. Zambrana JL, Velasco F, Castro P, Concha M, Valles F, Montilla P et al. Comparison of bezafibrate versus lovastin for lowering plasma insulin, fibrinogen and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients. Am J Cardiol 1997; 80: 836-840.
106. Kirschstein W, Simianer S, Dempfle E, Keller H, Stegarn B, Rentrop P et al. Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty. Thromb Haemost 1989; 62: 772-775.
107. Rifón J, Páramo JA, Panizo C, Montes R, Rocha E. The increase of plasminogen activator inhibitor activity is associated with graft occlusion in patients undergoing aorto-coronary bypass surgery. Br J Haematol 1997; 99: 262-267.
108. Eriksson P, Kallin B, Van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1.851-1.855.
109. Margaglione M, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, Grandone D et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 152-156.
110. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plaminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95: 59-62.
111. Estellés A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and patients with severe preeclampsia. Blood 1989; 74: 1.332-1.338.
112. Estellés A, Gilabert J, Keeton M, Eguchi Y, Aznar J, Grancha S et al. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood 1994; 84: 143-150.
113. Bergstein JM, Riley M, Bang NU. Role of plasminogen activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. N Engl J Med 1992; 327: 755-759.
114. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation. Circulation 1997; 96: 3.180-3.191.
115. Eitzman DT, McLoy RD, Zheng X, Fay WP, Shen T, Ginsburg D et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or everexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97: 232-237.